A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

NCT07658352 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

114

Enrollment

INDUSTRY

Sponsor class

Conditions

B-Cell Non-Hodgkin Lymphoma

Interventions

DRUG: HP-002

Sponsor

Shanghai Helioson Pharmaceutical Co., Ltd.